Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Biosafety Monitoring in Upstream Labs – V 2.0

Posted on By


Biosimilars: SOP for Biosafety Monitoring in Upstream Labs – V 2.0


Standard Operating Procedure for Biosafety Monitoring in Biosimilar Upstream Laboratories

Department Biosimilars
SOP No. SOP/BS/115/2025
Supersedes SOP/BS/115/2022
Page No. Page 1 of 12
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To establish a standardized procedure for biosafety monitoring in upstream laboratories handling biosimilar cell cultures to ensure the protection of personnel, containment of biological agents, and compliance with applicable GMP and biosafety regulations.

2. Scope

This SOP applies to all personnel and activities in upstream processing labs involved in cell banking, inoculation, bioreactor operations, and any processes using live recombinant or non-recombinant cell lines.

3. Responsibilities

  • Laboratory Staff: Adhere to biosafety protocols and report incidents or hazards.
  • Biosafety Officer: Conduct periodic risk assessments, review PPE compliance, and approve decontamination plans.
  • EHS Department: Monitor environmental biosafety indicators and coordinate training programs.

4. Accountability

The Head of Biosafety is accountable for the implementation, auditing, and improvement of biosafety practices in upstream labs.

5. Procedure

5.1 Biosafety Risk Assessment

  1. Conduct initial and annual risk assessments of all upstream activities.
  2. Identify hazards associated with:
    • Cell lines used (e.g., CHO, HEK293)
    • Vectors or viral components (if applicable)
    • Bioreactor effluent
  3. Classify activities as Biosafety Level 1 or 2 and document in Annexure-1.

5.2 Environmental Monitoring and Biosafety Controls

  1. Perform weekly swab testing of:
    • Workbenches
    • Door handles
    • Incubator interiors
  2. Monitor airborne microbial levels monthly using settle plates and RCS systems.
  3. Log all data in Annexure-2 and report out-of-spec to QA and Biosafety Officer.

5.3 PPE and Access Control Compliance

  1. Verify PPE adherence during lab walkthroughs:
    • Gloves, gowns, face shields, masks
  2. Restrict access to authorized staff via card-based or biometric entry.
  3. Non-compliance must be documented in deviation form and reviewed.

5.4 Incident Reporting and Spill Management

  1. All accidental exposures or spills must be reported within 15 minutes to the Biosafety Officer.
  2. Use SOP-defined disinfectants (1% sodium hypochlorite, 70% IPA) for cleanup.
  3. Submit Incident Report (Annexure-3) and investigate root cause within 48 hours.

5.5 Biosafety Audits

  1. Perform quarterly biosafety audits using a checklist approved by QA and EHS.
  2. Record findings in Annexure-4 and track CAPAs to closure.

6. Abbreviations

  • PPE: Personal Protective Equipment
  • EHS: Environment, Health, and Safety
  • RCS: Rotor Centrifugal Sampler
  • CAPA: Corrective and Preventive Action

7. Documents

  1. Biosafety Risk Assessment Form – Annexure-1
  2. Biosafety Monitoring Log – Annexure-2
  3. Incident Report Form – Annexure-3
  4. Biosafety Audit Checklist – Annexure-4

8. References

  • WHO Biosafety Manual, 4th Edition
  • OSHA Laboratory Safety Guidance

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Biosafety Risk Assessment Form

Process Hazard Identified Risk Level Control Measures Assessed By
MCB Expansion Spill exposure Moderate PPE, SOP cleanup Ajay Verma

Annexure-2: Biosafety Monitoring Log

Date Area Sample Type Result Remarks
04/05/2025 Incubator Room Swab No Growth Acceptable

Annexure-3: Incident Report Form

Date Incident Reported By Immediate Action Corrective Measure
03/05/2025 Media spill Sunita Reddy Cleaned with IPA Retrained on handling

Annexure-4: Biosafety Audit Checklist

Audit Area Checklist Point Compliant (Y/N) Remarks
Gowning Area Mask and gloves worn Y —

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Added audit procedure and updated PPE policy tracking Annual review update
See also  Biosimilars: SOP for Storage of Purified Bulk Product - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Sterile Injectable Manufacturing: SOP for Sanitization of Airlocks in Sterile Manufacturing Facilities – V 2.0
Next Post: Aerosol: SOP for Conducting Packaging Line Validation – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version